AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02240095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A - Online Clinical Questions Recorder
Description: Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
Study NCT02240095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B - Online Evidence Retrieval Coach
Description: Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
Study NCT02240095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C - Online Audit and Feedback
Description: Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
Study NCT00637208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venographic occlusion of spermatic veins
Description: Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
Study NCT00031486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
Study NCT00031486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
Study NCT03685591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)
Study NCT03685591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily
Study NCT02070484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NuCel
Study NCT02070484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Bone Matrix
Study NCT00101933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic DBS Therapy for epilepsy
Description: Stimulation On
Study NCT00101933 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medtronic DBS Therapy for epilepsy
Description: Stimulation Off
Study NCT00694005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kissing balloon
Description: simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
Study NCT00694005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without kissing balloon angioplasty leave alone
Description: simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
Study NCT01414621 — intervention group
Intervention type: OTHER
Intervention: atrial tissue sample
Description: atrial tissue sample from CABG patient
Study NCT03984370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207
Description: Abdominal SC administration
Study NCT03984370 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Abdominal SC administration
Study NCT00582309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucommander-Guided Intravenous Insulin Infusion
Description: Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels.
Study NCT00582309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intravenous Insulin Infusion
Description: Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here.
Study NCT00582309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Calculated Intravenous Insulin Infusion
Description: If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
Study NCT01931280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
Study NCT00353587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 200 mg once daily for 16 weeks
Study NCT00468741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Description: Full CHESS for subject use
Study NCT00468741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: informational services of CHESS available to subject
Study NCT00468741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: CHESS informational services and social support available to subject
Study NCT00981305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactate-containing vaginal lubricant
Description: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Study NCT00981305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal lubricant
Description: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Study NCT04713696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.
Study NCT04713696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine training
Description: Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
Study NCT03503357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing1
Description: Command List A
Study NCT03503357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 2
Description: Command List B
Study NCT03503357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 3
Description: Command List C
Study NCT03503357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 4
Description: Command List D
Study NCT03121001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
Study NCT03121001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
Study NCT03121001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
Study NCT00353587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 400 mg once daily for 16 weeks
Study NCT00353587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 600 mg once daily for 16 weeks
Study NCT00353587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MBX-102 Placebo once daily for 16 weeks
Study NCT00353587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: Actos 30 mg once daily for 16 weeks
Study NCT03547843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based education
Description: The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
Study NCT03547843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
Study NCT03547843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
Study NCT03547843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
Study NCT02472210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
Study NCT02472210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin
Description: An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
Study NCT02827006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corrective osteotomy distal radius
Description: Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
Study NCT02827006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corrective osteotomy distal radius
Description: Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
Study NCT04510675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Article
Description: Omeza Collagen Matrix
Study NCT04510675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: Occlusive Patch of 0.9% sodium chloride, NaCl
Study NCT04430751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical QiGong training
Description: The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization.
Study NCT03440684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program.
Study NCT01952184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CBSvit HS device
Description: closed vitrification with closed storage
Study NCT01952184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotop SC device
Description: open vitrification with closed storage
Study NCT00173108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinic-based intervention program and home-based intervention program
Description: The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
Study NCT01674374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01674374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01674374 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01674374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01674374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01674374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
Description: Given PO
Study NCT01185444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hya-Joint
Description: The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
Study NCT01185444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan
Description: The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
Study NCT04471155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holep
Description: laser enucleation of the gland versus open enucleation
Study NCT01551199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Channel Exposure Therapy- Veterans
Description: Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
Study NCT05559957 — intervention group
Intervention type: BEHAVIORAL
Intervention: observation of delivery and neonatal outcomes
Description: MONITORING THE DELIVERY MODE EITHER CESAREAN OR VAGINAL, BESIDE THE NEONATAL OUTCOME AND MORBIDITIES IN BOTH GROUPS
Study NCT01408355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273588
Description: Intravenous, 50 microgram, single dose
Study NCT01408355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273588
Description: Oral solution, 50 microgram, single dose
Study NCT00755040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion
Description: Given as eye drops
Study NCT00755040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given as eye drops
Study NCT02317393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: K5-RGD PET
Description: Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
Study NCT02317393 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FDG
Description: Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
Study NCT00976352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV1-CMV-GAA (study agent) Administration
Description: rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
Study NCT00976352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMST
Description: After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
Study NCT00977665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: rasagiline 1 mg tablet/day for 48 weeks
Study NCT00977665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet for 48 weeks
Study NCT01330433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoSeal Surgical Spray Group
Description: A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~* Patients weighing \< 3kg will receive 1ml of CoSeal~* Patients weighing 3-10kg will receive 1-2ml of CoSeal~* Patients weighing >10kg will receive 2-4ml of CoSeal
Study NCT02459730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with GIC containing 1.25% CHX.
Description: Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
Study NCT02459730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with GIC.
Description: Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
Study NCT02891057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-036)
Study NCT00668902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C]Pantoprazole
Description: \[13C\]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
Study NCT01038388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m² given IV or subcutaneously
Study NCT01038388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg given PO
Study NCT01038388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg given PO
Study NCT01038388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 100, 200, or 300 mg given PO
Study NCT03682835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FDGard
Description: capsule containing peppermint oil and caraway oil
Study NCT03682835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing cellulose
Study NCT02114151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
Study NCT02114151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
Study NCT00742638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
Study NCT00742638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: Sodium valproate tablet 200 mg
Study NCT01494584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezogabine/retigabine
Description: ezogabine dose escalation